Please assess the completion status of the following clinical trial:

Trial Title: The Nitazoxanide Plus Atazanavir for COVID-19 Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Willingness and ability to provide written informed consent~* At least 18 and not more than 75 years of age at study entry~* SARS-CoV-2 infection confirmed by PCR test within 4 days before randomization~* Currently symptomatic (fever or chills, cough, myalgia, sore throat, shortness of breath, or new onset of anosmia or ageusia) and at COVID-19 isolation and treatment centre~Exclusion Criteria:~* Inability to take orally administered medication or food~* Known hypersensitivity to study medication~* Pregnant or lactating (unless practicing exclusive replacement feeding for the entire study duration)~* Participation in any other interventional trial for COVID-19 (observational study co-enrollment allowed)~* Concurrent treatment with other agents with actual or possible direct-acting antiviral activity against SARS-CoV-2 less than 24 hours prior to study drug dosing~* Concurrent use of agents with known or uncertain interaction with study drugs, including ritonavir~* Requiring mechanical ventilation at screening~* Alanine Aminotransferase (ALT) or aspartate aminotransferase (AST) above 5 times upper limit of normal (ULN)~* Creatinine clearance below 50 mL/min using the Cockcroft-Gault formula for participants above 18 years of age

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Standard of Care (SOC) (Type: ACTIVE_COMPARATOR): Participants in this arm will receive SOC alone, which will be as determined by the clinical team at the treatment centres in line with the current National Interim Guidelines for Clinical Management of COVID-19
- SOC plus Intervention (Type: EXPERIMENTAL): Participants in this arm will receive SOC plus study intervention composed of orally administered nitazoxanide and atazanavir/ritonavir tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).